Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of obatoclax when given
together with bortezomib and to see how well they work in treating patients with relapsed or
refractory multiple myeloma. Obatoclax and bortezomib may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Giving obatoclax together with
bortezomib may kill more cancer cells.